Tabula Rasa HealthCare (NASDAQ:TRHC) Given a $78.00 Price Target at Piper Jaffray Companies

Share on StockTwits

Piper Jaffray Companies set a $78.00 price target on Tabula Rasa HealthCare (NASDAQ:TRHC) in a research report sent to investors on Friday, TipRanks reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Zacks Investment Research cut Tabula Rasa HealthCare from a buy rating to a hold rating in a research note on Thursday, October 10th. ValuEngine raised Tabula Rasa HealthCare from a buy rating to a strong-buy rating in a research note on Wednesday, September 4th. Stifel Nicolaus raised Tabula Rasa HealthCare from a hold rating to a buy rating and boosted their target price for the company from $50.00 to $75.00 in a research note on Friday, August 30th. Finally, BidaskClub cut Tabula Rasa HealthCare from a buy rating to a hold rating in a research note on Friday, October 11th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Tabula Rasa HealthCare has an average rating of Buy and an average price target of $78.26.

Shares of Tabula Rasa HealthCare stock opened at $48.92 on Friday. The company has a quick ratio of 1.90, a current ratio of 1.97 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare has a 12 month low of $40.86 and a 12 month high of $81.83. The business has a fifty day simple moving average of $54.91 and a 200 day simple moving average of $53.31. The stock has a market cap of $1.13 billion, a PE ratio of 143.88 and a beta of 1.66.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.29. Tabula Rasa HealthCare had a positive return on equity of 3.63% and a negative net margin of 7.09%. The business had revenue of $76.26 million during the quarter, compared to analysts’ expectations of $70.40 million. During the same period in the previous year, the firm earned $0.20 earnings per share. The firm’s quarterly revenue was up 56.9% compared to the same quarter last year. Analysts expect that Tabula Rasa HealthCare will post -0.15 EPS for the current fiscal year.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $53.85, for a total value of $430,800.00. Also, Director Gordon Tunstall sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $65.01, for a total value of $650,100.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 70,000 shares of company stock valued at $4,095,810. Insiders own 11.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Aperio Group LLC bought a new stake in shares of Tabula Rasa HealthCare in the second quarter valued at about $39,000. Nisa Investment Advisors LLC bought a new stake in shares of Tabula Rasa HealthCare in the third quarter valued at about $47,000. First Mercantile Trust Co. lifted its holdings in shares of Tabula Rasa HealthCare by 20.3% in the second quarter. First Mercantile Trust Co. now owns 1,197 shares of the company’s stock valued at $60,000 after purchasing an additional 202 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Tabula Rasa HealthCare in the second quarter valued at about $82,000. Finally, Bank of Montreal Can lifted its holdings in shares of Tabula Rasa HealthCare by 167.7% in the second quarter. Bank of Montreal Can now owns 2,605 shares of the company’s stock valued at $129,000 after purchasing an additional 1,632 shares in the last quarter. Institutional investors own 98.81% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Article: How does a security become overbought?

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Great Lakes Advisors LLC Cuts Stock Holdings in Jones Lang LaSalle Inc
Great Lakes Advisors LLC Cuts Stock Holdings in Jones Lang LaSalle Inc
Great Lakes Advisors LLC Boosts Stock Position in Martin Marietta Materials, Inc.
Great Lakes Advisors LLC Boosts Stock Position in Martin Marietta Materials, Inc.
Great Lakes Advisors LLC Sells 1,112 Shares of Gildan Activewear Inc
Great Lakes Advisors LLC Sells 1,112 Shares of Gildan Activewear Inc
Systematic Financial Management LP Makes New Investment in Tripadvisor Inc
Systematic Financial Management LP Makes New Investment in Tripadvisor Inc
Great Lakes Advisors LLC Sells 413 Shares of Netflix, Inc.
Great Lakes Advisors LLC Sells 413 Shares of Netflix, Inc.
NIC Inc.  Shares Sold by Systematic Financial Management LP
NIC Inc. Shares Sold by Systematic Financial Management LP


 
© 2006-2019 Zolmax.